Anne Burger

Chief Financial Officer, Co-Founder

Ms. Burger has over 15 years expertise in senior finance functions for biotech and Medtech companies throughout Europe and has served as lead advisor in numerous transactions, financings and structuring projects. Ms. Burger’s expertise and deep industry experience was instrumental in the financing of Breath Therapeutics and sale of the company to Zambon S.p.A. in 2019.

Recently, Ms. Burger was CFO for Rigontec GmbH, an immune-oncology biotechnology company. She supported Rigontec’s fundraising activities and had an active role in the execution of the Trade sale to MSD (deal volume up to 464 M€). Throughout her career, Ms. Burger held several CFO and advisor positions in the life sciences and healthcare sector and was responsible for fundraising, executing trade sales and licensing agreements, and preparing for IPOs.

Ms. Burger earned a graduate degree in Business Administration (Ludwig-Maximilian-Universität Munich, Honors) and successfully passed graduate studies in public health (Ludwig-Maximilian-Universität Munich).